Accordingly, an important mechanistic aspect of the curcumin and andrographis combined treatment is the dual suppression of GPX-4 and FSP-1, which has the potential to overcome the resistance of current chemotherapies and be beneficial to CRC patients in clinical practice. This evidence concerns the gene GPX4 and colorectal carcinoma.